Having an office here or not Is of no importance at all. As long as the company is domiciled here we enjoy enormous benefits. The cost of a duel listing is minuscule compared to the $4,000,000 received annually from the Australian government.
In in the agreement signed last year with Axovant, the Sydney office is listed for official correspondence. This has not changed. At some point in the future the company may be incorporated elsewhere but it will have zero impact on shareholders old or new.
The truth be told if we were based in the US from the beginning our valuation would have been up there with the best of them and capital would have poured in allowing us to take OPMD to market ourselves. Australian funds have no appetite or expertise in biotech. God bless America I say.
BLT Price at posting:
12.0¢ Sentiment: Buy Disclosure: Held
